Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease

José A Gómez-Puerta^1*, Sushrut S Waikar², Daniel H Solomon^1,3, Jun Liu³, Graciela S Alarcón⁴, Wolfgang C Winkelmayer⁵ and Karen H Costenbader¹

¹Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

²Division of Nephrology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

³Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

⁴Division of Rheumatology and Clinical Immunology, University of Alabama at Birmingham, Birmingham, AL, USA

⁵Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA

^*Corresponding Author: José A Gómez-Puerta, MD, PhD, MPH candidate, Section of Clinical Sciences, Division of Rheumatology, Immunology and Allergy, PBB-B3, Brigham and Women’s Hospital. 221 Longwood Ave, MA 02115, USA, Tel: 617-264-5908, Fax: 617-264-3019 Email: